KBP-336

KBP-336 is KeyBioscience's long-acting dual amylin and calcitonin receptor agonist (DACRA), dosed once-weekly subcutaneously, now in a Phase 2 trial (NCT06833749) in adults with obesity (BMI ≥30) and symptomatic knee osteoarthritis (Kellgren-Lawrence grade 2 or 3) [1]. The primary endpoint is proportional change in body weight, not pain - a tell that KeyBioscience is positioning this as a metabolic/obesity asset with a joint-disease wrapper, hunting for differentiation from the GLP-1 wave [1]. n=600 placebo-controlled, three active dose arms, recruiting, sponsor is a Swiss-headquartered subsidiary of Denmark's Nordic Bioscience with an existing strategic collaboration with Eli Lilly for the DACRA platform [2].

Novel compound, never approved anywhere. Phase 2 only - KeyBioscience has been working the DACRA class for over a decade through earlier candidates including KBP-042, KBP-089, and KBP-056, which Lilly licensed access to under the 2017 strategic collaboration; none have publicly advanced to late-stage trials [2]. No public FDA breakthrough, fast track, or orphan designation has been disclosed for KBP-336. The trial (NCT06833749) lists primary completion as November 2026 (estimated) per ClinicalTrials.gov, with a 6-month dosing duration; given that the trial is still recruiting toward n=600, typical enrollment slippage, and analysis time, a topline readout most likely lands in H2 2027 with downside risk into 2028 [1]. KeyBioscience is a fully owned subsidiary of Nordic Bioscience; current public financing disclosures are limited, and the Lilly collaboration (extended in 2024) is the most material source of non-dilutive funding [2]. There is no approved DACRA on the market, so KBP-336 would be first-in-class. Regulatory path for an obesity indication is well-trodden (semaglutide, tirzepatide), but an OA-in-obesity label would be novel and would require pain or function endpoints in a registrational trial - not just weight.

DACRAs hit two receptors at once. Amylin is a pancreatic hormone co-secreted with insulin that signals satiety to the brain and slows gastric emptying - pramlintide (an injected amylin analog approved for diabetes) and Novo's investigational cagrilintide work this way [3]. Calcitonin is a thyroid hormone that suppresses osteoclast activity and has been hypothesized to confer chondroprotective effects in OA models, though the molecular pathway (e.g., calcitonin-receptor-mediated suppression of MMP-13 or ADAMTS in chondrocytes) is not well established in published KBP-336 preclinical work [4]. A single molecule that does both is the bet: weight loss from the amylin side reduces mechanical load on knees, while calcitonin signaling provides bone protection and possibly antinociception. The mechanism is partially validated: amylin agonism produces weight loss in humans, and KBP-336 itself in a rat MNX OA model produced ~17% body weight loss in females and clear antinociception, plus suppression of bone resorption (CTX-I) sustained ~48 hours post-dose [4]. Importantly, that same paper reported KBP-336 did NOT preserve medial tibial cartilage in the model used - the authors attribute this to model severity, but the cartilage-protective claim is not yet supported by KBP-336-specific data [4]. The PK extension technology that makes KBP-336 'long-acting' (enabling once-weekly clinical dosing despite preclinical 72-hour dosing) has not been publicly disclosed by KeyBioscience. The competitive risk is that the dual mechanism doesn't beat GLP-1/GIP single-class agonists already delivering 15-20% weight loss.

NCT06833749 (KBP-336-CD-003) is a Phase 2 study in obese adults (BMI ≥30 kg/m²) with symptomatic knee OA (Kellgren-Lawrence grade 2 or 3 in target knee), n=600, recruiting, sponsored by KeyBioscience AG [1]. Design is placebo-controlled with three active KBP-336 dose arms, weekly subcutaneous injection, 6-month treatment duration [1]. The primary endpoint is proportional change in body weight from baseline to endpoint - striking, because the trial's clinical population is OA. That endpoint choice signals KeyBioscience is using the OA-in-obesity population as a regulatory wedge into the obesity market, with pain and function as secondary endpoints to support a future differentiated label. Secondary endpoints include WOMAC stiffness and function subscale changes, weekly NRS pain averages, WOMAC pain ≥30% and ≥50% responder rates, AQoL-8D quality of life, body composition and waist-to-hip ratio, and rescue medication usage - these are listed as secondary, not co-primary, and the public record does not state whether they are formally powered or exploratory [1]. No active comparator (semaglutide, tirzepatide) is included - a real weakness, because in 2026 the relevant question is not 'does it beat placebo' but 'how does it compare to drugs already on the market.' Without a head-to-head, even a clean readout leaves cross-trial comparison as the only commercial story, and those comparisons have historically been brutal for second-movers. No interim safety review is publicly disclosed in the ClinicalTrials.gov record.

Our model estimates a 11% chance this drug is eventually approved. It starts from the historical base rate for Phase 2 drugs in this area (about 35%), then adjusts using ten facts about the trial and sponsor. What moves the number most: it is helped by larger-than-typical enrollment for this phase; it is held back by heavier-than-usual blinding, the sponsor's thin or weak approval record, and weak or limited earlier-phase results. The other facts land near average for this stage, so they leave the estimate roughly where the base rate put it.

Efficacy risk is the dominant concern. The primary endpoint is weight loss, where the bar set by semaglutide (~15%) and tirzepatide (~20%) is brutal; pramlintide as a pure amylin agonist delivered ~2.4-2.8% placebo-subtracted weight loss in dedicated obesity trials (Aronne et al. 2007, J Clin Endocrinol Metab) [3], so KBP-336 needs the calcitonin arm to add meaningfully or the dual mechanism to synergize beyond additivity. Note pramlintide's effect in diabetes patients (its approved indication) is smaller still, so the 2.4-2.8% figure is the right benchmark for KBP-336's obesity-focused trial. If KBP-336 reads out at 5-8% weight loss, it's a scientific success and a commercial dead end. Safety risk: calcitonin receptor agonism has historical signals around nausea and injection-site reactions, and a long-term calcitonin/cancer signal flagged by EMA for salmon calcitonin remains a regulatory shadow over the class (note: SMC021 oral salmon calcitonin Phase 3 outcomes are referenced in the literature but a specific verified primary citation was not located for this writeup). Amylin agonists cause nausea and gastric effects similar to GLP-1s. Execution risk is real - KeyBioscience is small, n=600 is expensive, and the company has never run a registrational trial. The likely path is partnership-driven, and the existing Lilly collaboration is the natural conduit [2]. Commercial risk: even with clean data, payers facing GLP-1 budget pressure will not cover a first-in-class DACRA without head-to-head superiority or a clearly differentiated OA structural benefit - and the trial isn't designed for the former, while KBP-336's own preclinical data did not show cartilage preservation in the model tested [4].

Worth watching, but at low priority until the readout. The signal to watch is not Phase 2 success or failure in absolute terms - it's the magnitude of weight loss relative to ~15% semaglutide and ~20% tirzepatide, and whether KeyBioscience reports any cartilage/pain benefit beyond load reduction that would justify the OA framing. The strongest M&A lead is Eli Lilly: Lilly has held a strategic collaboration on the DACRA platform since 2017 and extended it in 2024 [2]. That is a real, named partnership - not the vague 'Novo Nordisk historical ties' an earlier version of this writeup asserted (which was unsupported and removed). If KBP-336 delivers >10% weight loss plus a structural OA signal, Lilly is the natural acquirer/optioner; if not, the program likely stalls absent renewed Lilly interest. Per ClinicalTrials.gov, primary completion is estimated November 2026 with 6-month dosing - readout most likely H2 2027, with slippage risk into 2028. Until then, the relevant tells are (a) any expansion of the Lilly collaboration scope, (b) interim safety updates, and (c) Phase 1 KBP-336 results, which we could not locate in the public record - that silence is itself a mild negative signal for a Phase 2 asset. No reason to act on this now.